Conference Program

CONFERENCE PROGRAM

Topic

Speaker

9.00-9.10am

Welcome Speech

Honorable Fiona Patten MP

9.10-9.40am

The Endocannabinoid System, Moods and Mental Health

Dr Stephanie Robinson PhD

9.40-10.10am

Overview of Medicinal Cannabis

Prof Kylie O’Brien PhD, Torrens University & Adjunct Fellow NICM Health Research Institute, Western Sydney University

10.10-10.40am

Medicinal Cannabis: Delivery Methods, Pharmacokinetics/Dynamics and Safety

Mr Justin Sinclair, NICM Health Research Institute, Western Sydney University

10.45-11.15am

MORNING TEA

11.15-11.45am

Treating Anxiety and Depression with Medicinal Cannabis

Dr Sue Sisley MD (United States)

11.45-12.15pm

Nutritional Medicine Management of Mental Health

Ms Rachel Arthur, Naturopath

12.15-12.45pm

The Gut Microbiome, Moods & Mental Health

Prof Luis Vitetta PhD University of Sydney

12.45-1.00pm

Q&A

All speakers

1.00-2.00pm

LUNCH

2.00-2.30pm

PTSD and Medicinal Cannabis

Dr Sue Sisley MD (United States)

2.30-3.00pm

Case Study Co-Morbid Chronic Pain and Depression: Treatment with Medicinal Cannabis

Dr Teresa Towpik, General Practitioner

3.00-3.30pm

Insomnia: Treatment with Medicinal Cannabis

Dr Sinclair Bode, General Practitioner

3.30-400pm

AFTERNOON TEA

4.00-4.30pm

Safety of Cannabis: Addiction, Psychosis & the Effect on the Developing Brain

Professor Nick Lintzeris

University of Sydney

4.30-5.00pm

Medicinal Cannabis in Treatment of Alzheimer’s Disease

Dr Genevieve Steiner PhD (NICM) Health Research Institute, Western Sydney University

5.00-5.20pm

Medicinal Cannabis: Where to Next?

Prof Ian Brighthope, Founder ACNEM

5.20-5.40

Q&A

All speakers

5.45 pm

CLOSE

Note: GHI (Aus) Ltd reserves the right to make changes to the conference and Masterclass programs, including speakers, where necessary.

LEARNING OUTCOMES

At the end of the conference, healthcare practitioners should be able to:

  1. Describe the endocannabinoid system and argue the physiological basis for potential efficacy of medicinal cannabis.
  2. Differentiate various forms of medicinal cannabis and their routes of delivery, including how these impact therapeutically.
  3. Argue the evidence base for the use of medicinal cannabis in a range of mental health conditions.
  4. Discuss the importance of gut health in relation to mental health, and provide advice on some nutritional medicine approaches to improving mental health.
  5. Evaluate evidence associated with safety of medicinal cannabis, including differentiating data associated with recreational versus medicinal use.

CONTINUING PROFESSIONAL DEVELOPMENT (CPD)

POINTS

Attendees of the conference may be able to claim CPD points from their professional association. Please apply to your association directly. A certificate of attendance is provided.

Pending Category 2 CPD points approval from the Royal Australasian College of General Practitioners.

CONFERENCE SPONSORS

blank
View Sponsor Bio

Phoenix Life Sciences International Limited is an adaptive healthcare solutions company. The Company’s main initiatives are to advance research on medicinial cannabis and and manufacture cannabis-based products that target and treat diabetes, pain, cancer, and address psychological, gastrointestinal, autoimmune, neurological and sleep disorders. The Company is working with developing nations on integrative programs to improve affordable healthcare and creating industry.  

blank
View Sponsor Bio

VIVO Cannabis’ Beacon Medical brand offers pharmaceutical-grade products grown in small batches at our state-of-the-art facility in Napanee, Ontario. Beacon Medical turns these plants into a variety of Cannabis products for patients to treat their disease. Our focus and pharmaceutical heritage mean that we implicitly understand the needs of prescribing physicians and their patients; and we provide a unique and simplified approach to navigating medical cannabis using the Beacon Cannatypes™ classification system. Beacon Medical is committed to the education of the community and health- care professionals who are interested in learning about Medicinal Cannabis;
and to ensuring that Australian patients have access to safe cannabis medicines.

blank
View Sponsor Bio

Tilray is a global leader in medical cannabis ciltivation, production and research, offering a range of cannabinoid products to patients. pharmaicies and researchers in the European Union, Australia, Canada and the Americas.  

blank
View Sponsor Bio

Entoura is an Australian operated healthcare company, developing and supplying high quality medicinal cannabis products. Established by Professor Ian Brighthope, who over 40 years ago founded Nutrition Care Pharmaceuticals, one of Australia’s exclusive companies in its ability to both formulate and manufacture therapeutic nutraceutical medicines. Entoura is committed to the development of high-quality innovative therapeutics that are supported by outstanding research programs, validated with clinical evidence and disseminated via exceptional education programs. Entoura is active in the Medicinal Cannabis industry, supporting medicinal cannabis research, education, manufacturing and patient access. Our vision is to open new pathways for previously inaccessible practitioner – patient treatment intervention.

blank
View Sponsor Bio

Bio Coming Soon!